Inducible immortality in hTERT-human mesenchymal stem cells

Journal of Orthopaedic Research

Volumn 30, Issue 12, 2012, Pages 1879-1885

  Piper, Samantha L ^a   Wang, Miqi ^b   Yamamoto, Akira ^a   Malek, Farbod ^b   Luu, Andrew ^b   Kuo, Alfred C ^a,b   Kim, Hubert T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

immortalized; mesenchymal stem cell; multipotential; telomerase

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 2; DOXYCYCLINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PROTEOGLYCAN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR RUNX2;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; STEM CELL TRANSPLANTATION; TELOMERE; TISSUE ENGINEERING; WILD TYPE;

ADIPOGENESIS; ADULT; BONE MARROW CELLS; CELL AGING; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; DOXYCYCLINE; GENE EXPRESSION REGULATION; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; PLASMIDS; STEM CELLS; TELOMERASE; TELOMERE; TISSUE ENGINEERING;

EID: 84867854263     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22162     Document Type: Article

References (36)

1. Brittberg M, Lindhal A, Nilsson A, et al. 1994. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331: 889-895.
2. Parsch D, Fellenberg J, Brummendorf TH, et al. 2004. Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. J Mol Med 82: 49-55.
3. Knutsen G, Engebretsen L., 2004. A randomized trial of autologous chondrocyte implantation compared with microfracture in the knee. J Bone Joint Surg Am 86: 455-464.
4. Steinert AF, Ghivizzani SC, Rethwilm A., 2007. Major biological obstacles for persistent cell-based regeneration of articular cartilage. Arthritis Res Therapy 9: 213.
5. Pittenger MF, Mackay AM, Beck SC, et al. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
6. Le Blanc K, Rongden O., 2007. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262: 509-525.
7. Christiansen M, Kveiborg M, Kassem M, et al. 2000. CBFA1 and topoisomerase 1 mRNA labels decline during cellular aging of human trabecular osteoblasts. J Gerontol A Biol Sci Med Sci 55: B194-B200.
8. Herbig U, Jobling WA, Chen PCB, et al. 2004. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but Not p16INK4a. Mol Cell 14: 501-513.
9. Gronthos S, Chen S, Wang CY, et al. 2003. Telomerase accelerates osteogenesis of MSCs by up regulation of CBFA1, osterix and osteocalcin. J Bone Mineral Res 18: 716-722.
10. Simonsen JL, Rosada C, Serakinci N, et al. 2002. Telomerase expression extends the proliferative lifespan and maintains oseogenic potential of human bone marrow stromal cells. Nat Biotechnol 20: 592-596.
11. Yudoh K, Nishioka K., 2004. Telomerized presenescent osteoblasts prevent bone mass loss in vivo. Gene Therapy 11: 909-915.
12. Shi S, Gronthos S, Chen S, et al. 2002. Bone formation by human postnatal bon marrow stromal stem cells is enhanced by telomerase expression. Nat Biotech 20: 587-591.
13. Tsai C, Chen C, Liu H, et al. 2010. Overexpression of hTERT increases stem-like properties and decreases spontaneous differentiation in hMSC lines. J Biomed Sci 17: 64.
14. Yang J, Cao C, Wang W, et al. 2010. Proliferation and osteogenesis of immortalized bone marrow-derived mesenchymal stem cells in porous polylactic glycolic acid scaffolds under perfusion culture. J Biomed Mater Res 92A: 817-829.
15. Hung C, Yao C, Cheng F, et al. 2010. Establishment of immortalized mesenchymal stromal cells with red fluorescence protein expression for in vivo transplantation and tracing in the rat model with traumatic brain injury. Cytotherapy 12: 455-465.
16. Nakahara H, Misawa H, Hayashi T, et al. 2009. Bone repair by transplantation of hTERT-immortalized human mesenchymal stem cells in mice. Transplantation 88: 346-353.
17. Blackburn EH., 2005. Telomeres and telomerase: their mechanisms of action and the effects of altering their function. FEBS Let 579: 859-862.
18. Chiang YJ, Hemann MT, Hathcock KS, et al. 2004. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 24: 7024-7031.
19. Sarin KY, Cheung P, Gilison D, et al. 2005. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 1048-1052.
20. Burns JS, Abdallah BM, Guldberg P, et al. 2005. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of hTERT-MSCs. Cancer Res 65: 3126-3135.
21. Li N, Yang R, Zhang W, et al. 2009. Genetically transforming human mesenchymal stem cells to sarcomas. Cancer 115: 4795-4806.
22. Huang G, Zheng Q, Sun J, et al. 2008. Stabilization of cellular properties and differentiation of mutilpotential of human mesenchymal stem cells transduced with hTERT gene in a long-term culture. J Cell Biochem 103: 1256-1269.
23. Huang G, Pan Z, Huang J, et al. 2008. Proteomic analysis of human bone marrow mesenchymal stemcells transduced with human telomerase reverse transcriptase gene during proliferation. Cell Prolif 41: 625-644.
24. Kelland LR., 2005. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur J Cancer 41: 971-979.
25. White LK, Wright WE., 2001. Telomerase inhibitors. Trends Biotechnol 19: 114-120.
26. Kassem M, Ankersen L, Eriksen EF, et al. 1997. Demonstration of cellular aging and senescence in serially passaged long-term cultures of human osteoblasts. Osteoporosis 7: 514-524.
27. Jiang XR, Jimenez G, Chang E, et al. 1999. Telomeraseexpression in human somatic cells does not inducechanges associated with a transformed phenotype. Nat Genet 21: 111-114.
28. Morales CP, Holt SE, Ouellette M, et al. 1999. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21: 115-118.
29. Wang J, Hannon GJ., 2000. Risky immortalization by telomerase. Nature 405: 755-756.
30. Farwell DG, Shera KA, Koop JI, et al. 2000. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol 156: 1537-1547.
31. Lindvall C, Hou M, Komurasaki T, et al. 2003. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 63: 1743-1747.
32. Noble JR, Zhong ZH, Neumann AA, et al. 2004. Alterations in the p16 (INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene 23: 3116-3121.
33. Mondello C, Chiesa M, Rebuzzini P, et al. 2003. Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals. Biochem Biophys Res Commun 308: 914-921.
34. Milyavsky M, Shats I, Erez N, et al. 2003. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res 63: 7147-7157.
35. Serakinci N, Guldberg P, Burns JS, et al. 2004. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23: 5095-5098.
36. Sipo I, Picõ AH, Wang W, et al. 2006. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 84: 215-225.